These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 33579785)

  • 21. The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
    Floris G; Sciot R; Wozniak A; Van Looy T; Wellens J; Faa G; Normant E; Debiec-Rychter M; Schöffski P
    Clin Cancer Res; 2011 Sep; 17(17):5604-14. PubMed ID: 21737509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Translational insights into gastrointestinal stromal tumor and current clinical advances.
    Hemming ML; Heinrich MC; Bauer S; George S
    Ann Oncol; 2018 Oct; 29(10):2037-2045. PubMed ID: 30101284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Surgical Management of Metastatic Gastrointestinal Stromal Tumors.
    Yonkus JA; Alva-Ruiz R; Grotz TE
    Curr Treat Options Oncol; 2021 Mar; 22(5):37. PubMed ID: 33743084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ripretinib and MEK Inhibitors Synergize to Induce Apoptosis in Preclinical Models of GIST and Systemic Mastocytosis.
    Gupta A; Singh J; García-Valverde A; Serrano C; Flynn DL; Smith BD
    Mol Cancer Ther; 2021 Jul; 20(7):1234-1245. PubMed ID: 33947686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New targets and therapies for gastrointestinal stromal tumors.
    Wozniak A; Gebreyohannes YK; Debiec-Rychter M; Schöffski P
    Expert Rev Anticancer Ther; 2017 Dec; 17(12):1117-1129. PubMed ID: 29110548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gastrointestinal stromal tumours.
    Blay JY; Kang YK; Nishida T; von Mehren M
    Nat Rev Dis Primers; 2021 Mar; 7(1):22. PubMed ID: 33737510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anagrelide for Gastrointestinal Stromal Tumor.
    Pulkka OP; Gebreyohannes YK; Wozniak A; Mpindi JP; Tynninen O; Icay K; Cervera A; Keskitalo S; Murumägi A; Kulesskiy E; Laaksonen M; Wennerberg K; Varjosalo M; Laakkonen P; Lehtonen R; Hautaniemi S; Kallioniemi O; Schöffski P; Sihto H; Joensuu H
    Clin Cancer Res; 2019 Mar; 25(5):1676-1687. PubMed ID: 30530703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors.
    Banks E; Grondine M; Bhavsar D; Barry E; Kettle JG; Reddy VP; Brown C; Wang H; Mettetal JT; Collins T; Adeyemi O; Overman R; Lawson D; Harmer AR; Reimer C; Drew L; Packer MJ; Cosulich S; Jones RD; Shao W; Wilson D; Guichard S; Fawell S; Anjum R
    Sci Transl Med; 2020 Apr; 12(541):. PubMed ID: 32350132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
    Tang CM; Lee TE; Syed SA; Burgoyne AM; Leonard SY; Gao F; Chan JC; Shi E; Chmielecki J; Morosini D; Wang K; Ross JS; Kendrick ML; Bardsley MR; Siena M; Mao J; Harismendy O; Ordog T; Sicklick JK
    Oncotarget; 2016 Nov; 7(48):78226-78241. PubMed ID: 27793025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Durable tumor regression in highly refractory metastatic
    Schroeder BA; Kohli K; O'Malley RB; Kim TS; Jones RL; Pierce RH; Pollack SM
    Oncoimmunology; 2020; 9(1):1710064. PubMed ID: 32002307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heterogeneity of kinase inhibitor resistance mechanisms in GIST.
    Liegl B; Kepten I; Le C; Zhu M; Demetri GD; Heinrich MC; Fletcher CD; Corless CL; Fletcher JA
    J Pathol; 2008 Sep; 216(1):64-74. PubMed ID: 18623623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.
    Serrano-Candelas E; Ainsua-Enrich E; Navinés-Ferrer A; Rodrigues P; García-Valverde A; Bazzocco S; Macaya I; Arribas J; Serrano C; Sayós J; Arango D; Martin M
    Mol Oncol; 2018 Aug; 12(8):1383-1397. PubMed ID: 29885053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
    Cohen NA; Zeng S; Seifert AM; Kim TS; Sorenson EC; Greer JB; Beckman MJ; Santamaria-Barria JA; Crawley MH; Green BL; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Cancer Res; 2015 May; 75(10):2061-70. PubMed ID: 25836719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells.
    Sako H; Fukuda K; Saikawa Y; Nakamura R; Takahashi T; Wada N; Kawakubo H; Takeuchi H; Ohmori T; Kitagawa Y
    PLoS One; 2014; 9(9):e107613. PubMed ID: 25221952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
    Lai S; Wang G; Cao X; Luo X; Wang G; Xia X; Hu J; Wang J
    Oncotarget; 2016 Jan; 7(2):1367-79. PubMed ID: 26587973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.
    Ganjoo KN; Villalobos VM; Kamaya A; Fisher GA; Butrynski JE; Morgan JA; Wagner AJ; D'Adamo D; McMillan A; Demetri GD; George S
    Ann Oncol; 2014 Jan; 25(1):236-40. PubMed ID: 24356634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
    Du J; Wang S; Wang R; Wang SY; Han Q; Xu HT; Yang P; Liu Y
    Pathol Oncol Res; 2020 Jan; 26(1):91-100. PubMed ID: 31758409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting the WEE1 kinase strengthens the antitumor activity of imatinib via promoting KIT autophagic degradation in gastrointestinal stromal tumors.
    Liu W; Zeng X; Yin Y; Li C; Yang W; Wan W; Shi L; Wang G; Tao K; Zhang P
    Gastric Cancer; 2020 Jan; 23(1):39-51. PubMed ID: 31197522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unbiased compound screening identifies unexpected drug sensitivities and novel treatment options for gastrointestinal stromal tumors.
    Boichuk S; Lee DJ; Mehalek KR; Makielski KR; Wozniak A; Seneviratne DS; Korzeniewski N; Cuevas R; Parry JA; Brown MF; Zewe J; Taguchi T; Kuan SF; Schöffski P; Debiec-Rychter M; Duensing A
    Cancer Res; 2014 Feb; 74(4):1200-13. PubMed ID: 24385214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.